What it sells
AI simulations of clinical trials for pharma
Business model breakdown
Buyer: who owns the budget?
Clinical development, business development and portfolio teams at pharma.
Trigger: what makes them buy now?
Pharma sponsors facing tight timelines or budgets for trial protocol design (case study: a protocol target within 9 months on a shrinking budget) and launch risk (site cites 1 in 3 drugs missing launch forecasts).
Workflow: what inputs become what output?
Adjust protocol parameters (arms, endpoints, criteria) and instantly see simulated effect on outcomes, feasibility, cost.
Economics: what it saves and how it charges
Claims up to 90% predictive accuracy across 600+ simulated trials.
Distribution: how it reaches customers
Enterprise sales; Request a Demo.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-08-04 | Series B | $45M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.